Furthermore, a new anti-PDL-1 inhibitor (envafolimab) has started phase 1 trials in the US and Japan and a phase 2 registration trial in China with MSI-H tumor patients or in combination as a phase 3 registration trial in cholangiocarcinoma patients [3]. This evidence concerns the gene CD274 and neoplasm.